ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 198 filers reported holding ROYALTY PHARMA PLC in Q4 2020. The put-call ratio across all filers is 2.07 and the average weighting 1.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $18,158,046 | -12.0% | 669,051 | -0.4% | 0.02% | -10.0% |
| Q2 2023 | $20,642,495 | +14.5% | 671,519 | +34.2% | 0.02% | +11.1% |
| Q1 2023 | $18,034,132 | +11.2% | 500,531 | +21.9% | 0.02% | +5.9% |
| Q4 2022 | $16,223,236 | -2.6% | 410,507 | -0.9% | 0.02% | -10.5% |
| Q3 2022 | $16,650,000 | -0.7% | 414,398 | +4.0% | 0.02% | +11.8% |
| Q2 2022 | $16,759,000 | +16.3% | 398,610 | +7.7% | 0.02% | +41.7% |
| Q1 2022 | $14,416,000 | +36.6% | 369,981 | +39.7% | 0.01% | +100.0% |
| Q4 2021 | $10,550,000 | +88.0% | 264,792 | +70.5% | 0.01% | +100.0% |
| Q3 2021 | $5,612,000 | -9.3% | 155,312 | +2.9% | 0.00% | 0.0% |
| Q2 2021 | $6,185,000 | +22.3% | 150,884 | +30.1% | 0.00% | 0.0% |
| Q1 2021 | $5,056,000 | +15.3% | 115,947 | +32.4% | 0.00% | +50.0% |
| Q4 2020 | $4,384,000 | – | 87,579 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $244,378,000 | 79.54% |
| Vantage Consulting Group Inc | 7,862,542 | $284,152,000 | 60.85% |
| Memorial Sloan Kettering Cancer Center | 2,680,644 | $96,878,000 | 60.36% |
| Indie Asset Partners, LLC | 701,323 | $25,346,000 | 20.53% |
| HARVARD MANAGEMENT CO INC | 7,142,856 | $258,143,000 | 15.13% |
| Bleichroeder LP | 1,115,980 | $40,332,000 | 6.55% |
| Overbrook Management Corp | 785,132 | $28,375,000 | 6.16% |
| Geo Capital Gestora de Recursos Ltd | 194,305 | $7,022,000 | 3.21% |
| Brown University | 621,759 | $22,470,000 | 3.05% |
| Graypoint LLC | 610,584 | $22,067,000 | 2.71% |